These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22119926)

  • 1. Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines.
    Salvador A; Igartua M; Hernández RM; Pedraz JL
    Vaccine; 2012 Jan; 30(3):589-96. PubMed ID: 22119926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(d,l)-lactide-co-glycolide (PLGA) microspheres as immunoadjuvant for Brugia malayi antigens.
    Saini V; Verma SK; Murthy PK; Kohli D
    Vaccine; 2013 Aug; 31(38):4183-91. PubMed ID: 23827312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
    Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
    Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(lactide-co-glycolide) microspheres: a potent oral delivery system to elicit systemic immune response against inactivated rabies virus.
    Ramya R; Verma PC; Chaturvedi VK; Gupta PK; Pandey KD; Madhanmohan M; Kannaki TR; Sridevi R; Anukumar B
    Vaccine; 2009 Mar; 27(15):2138-43. PubMed ID: 19356617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen.
    Saini V; Jain V; Sudheesh MS; Jaganathan KS; Murthy PK; Kohli DV
    Int J Pharm; 2011 Apr; 408(1-2):50-7. PubMed ID: 21291968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
    Jaganathan KS; Vyas SP
    Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
    Quintilio W; Kubrusly FS; Iourtov D; Miyaki C; Sakauchi MA; Lúcio F; Dias Sde C; Takata CS; Miyaji EN; Higashi HG; Leite LC; Raw I
    Vaccine; 2009 Jun; 27(31):4219-24. PubMed ID: 19393709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties.
    Wang T; Jiang H; Zhao Q; Wang S; Zou M; Cheng G
    Int J Pharm; 2012 Oct; 436(1-2):351-8. PubMed ID: 22721849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
    San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
    Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres.
    Kirby DJ; Rosenkrands I; Agger EM; Andersen P; Coombes AG; Perrie Y
    J Drug Target; 2008 Aug; 16(7):543-54. PubMed ID: 18686124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.
    Feng L; Qi XR; Zhou XJ; Maitani Y; Wang SC; Jiang Y; Nagai T
    J Control Release; 2006 May; 112(1):35-42. PubMed ID: 16516999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.
    Carcaboso AM; Hernández RM; Igartua M; Rosas JE; Patarroyo ME; Pedraz JL
    Vaccine; 2004 Mar; 22(11-12):1423-32. PubMed ID: 15063565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo validation of biological responses of bFGF released from microspheres formulated by blending poly-lactide-co-glycolide and poly(ethylene glycol)-grafted-chitosan in hamster cheek pouch microcirculatory models.
    Falabella CA; Jiang H; Frame MD; Chen W
    J Biomater Sci Polym Ed; 2009; 20(7-8):903-22. PubMed ID: 19454159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.
    Mossman SP; Evans LS; Fang H; Staas J; Tice T; Raychaudhuri S; Grabstein KH; Cheever MA; Johnson ME
    Vaccine; 2005 May; 23(27):3545-54. PubMed ID: 15855013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides.
    Mata E; Igartua M; Hernández RM; Rosas JE; Patarroyo ME; Pedraz JL
    Drug Deliv; 2010; 17(7):490-9. PubMed ID: 20500129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB; Bhat AA; Sah A; Donthamshetty RN
    Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.